{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:58:14Z","timestamp":1783353494907,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biologic medications have dramatically enhanced the treatment of many chronic paediatric inflammatory conditions. Their high cost is a factor that prohibits their broader use. Cheaper generic versions, or biosimilars, are increasingly being used. Healthcare services are switching some patients over to biosimilars for economic reasons, known as \u2018non-medical switching\u2019. Some patients unsuccessfully switch due to perceived decreases in efficacy or non-specific drug effects. The implications of failed switching include exhaustion of therapeutic options, unnecessary exposure to other medications, increased healthcare utilisation, worse patient outcomes and higher overall healthcare costs. Patient perceptions almost certainly play a role in these \u2018failed switches\u2019.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A thematic analysis was performed to better understand patient and parent perceptions on non-medical biosimilar switching. The study was conducted in accordance with the Consolidated Criteria for Reporting Qualitative Research recommendations. Patients with juvenile idiopathic arthritis currently taking adalimumab were included.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine families were interviewed just prior to a hospital trust-wide non-medical switch to an adalimumab biosimilar. Several common themes were identified. The most frequent concerns were regarding practical aspects of the switch including the medication administration device type; the colour of the medication and administration device; and whether the injections would sting more. The relative safety and efficacy of the biosimilar was raised although most families felt that there would be no significant difference. Anxieties about the switch were largely placated by reassurances from the medical team.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We derived recommendations based on existing adult literature and the observations from our study to optimise the benefits from non-medical biosimilar switching.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-019-0366-x","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T14:03:40Z","timestamp":1570197820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9631-4455","authenticated-orcid":false,"given":"William D.","family":"Renton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leveret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Smee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Leveret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"issue":"8","key":"366_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"366_CR2","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-out cohort. Ann Rheum Dis. 2015;74(10):1854\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"366_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"366_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-018-0266-5","volume":"16","author":"M Cann","year":"2018","unstructured":"Cann M, Ramanan AV, Crawford A, Dick AD, Clarke SLN, Rashed F, et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16(1):51.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"suppl_4","key":"366_CR5","doi-asserted-by":"publisher","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","volume":"56","author":"AG Vulto","year":"2017","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2017;56(suppl_4):iv14\u201329.","journal-title":"Rheumatology (Oxford)"},{"key":"366_CR6","unstructured":"European Medicines Agency (EMA). Biosimilar medicines: overview 2018 [cited 2018 12\/12\/2018]. Available from: \n                    https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines\n                    \n                  ."},{"issue":"2","key":"366_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/rheumatology\/kew206","volume":"56","author":"N Goel","year":"2017","unstructured":"Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017;56(2):187\u201397.","journal-title":"Rheumatology (Oxford)"},{"issue":"20","key":"366_CR8","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1002\/sim.7814","volume":"37","author":"RE Weiss","year":"2018","unstructured":"Weiss RE, Xia X, Zhang N, Wang H, Chi E. Bayesian methods for analysis of biosimilar phase III trials. Stat Med. 2018;37(20):2938\u201353.","journal-title":"Stat Med"},{"issue":"10","key":"366_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/archdischild-2017-312994","volume":"102","author":"N Ruperto","year":"2017","unstructured":"Ruperto N, Brunner HI, Lovell DJ, Martini A. Paediatric rheumatology international trials O, the pediatric rheumatology collaborative study G. extrapolation or controlled trials in paediatrics: the current dilemma. Arch Dis Child. 2017;102(10):949\u201351.","journal-title":"Arch Dis Child"},{"issue":"2","key":"366_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"366_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","volume":"16","author":"H Lee","year":"2014","unstructured":"Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16(1):22\u20136.","journal-title":"AAPS J"},{"issue":"3","key":"366_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.40388","volume":"70","author":"SL Bridges Jr","year":"2018","unstructured":"Bridges SL Jr, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, et al. The science behind Biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70(3):334\u201344.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"366_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/conmed-2017-100005","volume":"1","author":"V Azevedo","year":"2017","unstructured":"Azevedo V, D\u00f6rner T, Strohal R, Isaacs J, Casta\u00f1eda-Hern\u00e1ndez G, Gon\u00e7alves J, et al. Biosimilars: considerations for clinical practice. Considerations in Medicine. 2017;1(1):13\u20138.","journal-title":"Considerations in Medicine"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2017.02.003","volume":"79","author":"Y Komaki","year":"2017","unstructured":"Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases; a systematic review and meta-analysis. J Autoimmun. 2017;79:4\u201316.","journal-title":"J Autoimmun"},{"key":"366_CR15","doi-asserted-by":"crossref","unstructured":"Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2018.","DOI":"10.1136\/annrheumdis-2018-213474"},{"issue":"5","key":"366_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"J Avouac","year":"2018","unstructured":"Avouac J, Molto A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University hospital, Paris. France Semin Arthritis Rheum. 2018;47(5):741\u20138.","journal-title":"France Semin Arthritis Rheum"},{"issue":"1","key":"366_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective complaints as the Main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"366_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","volume":"147","author":"F Benedetti","year":"2007","unstructured":"Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147(2):260\u201371.","journal-title":"Neuroscience"},{"key":"366_CR19","doi-asserted-by":"crossref","unstructured":"Decock D, Davies R, Kearsley-Fleet L, Baildam E, Beresford M, Foster H, et al. P34\u2003Biosimilar use in children and young people with juvenile idiopathic arthritis in a real-world setting in the United Kingdom. Rheumatology. 2018;57(suppl_8):key273.036-key273.036.","DOI":"10.1093\/rheumatology\/key273.036"},{"key":"366_CR20","doi-asserted-by":"crossref","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol. 2018.","DOI":"10.1038\/s41584-018-0110-9"},{"key":"366_CR21","unstructured":"Braun V, Clarke V. Successful qualitative research: a practical guide for beginners: sage; 2013."},{"key":"366_CR22","unstructured":"Crabtree BF, Miller WL. Doing qualitative research: Sage publications; 1999."},{"issue":"6","key":"366_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"366_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature working G. standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"366_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jpain.2015.10.010","volume":"17","author":"P Reicherts","year":"2016","unstructured":"Reicherts P, Gerdes AB, Pauli P, Wieser MJ. Psychological placebo and nocebo effects on pain rely on expectation and previous experience. J Pain. 2016;17(2):203\u201314.","journal-title":"J Pain"},{"key":"366_CR26","unstructured":"J\u00f8rgensen TS, Skougaard M, Asmussen HC, Lee A, Taylor PC, Gudbergsen H, et al. Communication strategies are highly important to avoid nocebo effect when performing non-medical switch from originator product to biosimilar product: Danish results from applying the Parker model a qualitative 3-step research model. Arthritis Rheumatol. 2017;69."},{"issue":"5","key":"366_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397\u2013404.","journal-title":"BioDrugs"},{"issue":"11","key":"366_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023603","volume":"8","author":"MI Aladul","year":"2018","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open. 2018;8(11):e023603.","journal-title":"BMJ Open"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0366-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T23:12:10Z","timestamp":1601680330000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0366-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was prospectively approved by the University Hospitals Bristol Questionnaire, Interview & Survey Group. Informed, written consent to participate was obtained at the time of recruitment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed, written consent to publish anonymised data was obtained at the time of recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests are declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}